Cargando…

Clot stability as a determinant of effective factor VIII replacement in hemophilia A

ESSENTIALS: Factor VIII (FVIII) replacement in hemophilia A corrects bleeding due to low thrombin generation. There is uncertainty about the minimal or trough level of FVIII needed for optimal treatment. FVIII improves physical properties of hemophilia clots, including stiffness and permeability. Fi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leong, Lilley, Chernysh, Irina N., Xu, Yifan, Sim, Derek, Nagaswami, Chandrasekaran, de Lange, Zelda, Kosolapova, Sofia, Cuker, Adam, Kauser, Katalin, Weisel, John W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles: Haemostasis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920517/ https://www.ncbi.nlm.nih.gov/pubmed/29713693 http://dx.doi.org/10.1002/rth2.12034

Ejemplares similares

Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation
por: Valke, Lars L.F.G., et al.
Publicado: (2020)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Fibrin Clots Are Equilibrium Polymers That Can Be Remodeled Without Proteolytic Digestion
por: Chernysh, Irina N., et al.
Publicado: (2012)

Thrombin‐generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause
por: Hofer, Stefanie, et al.
Publicado: (2019)

Joint status of patients with nonsevere hemophilia A
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022)

Validation of PROMIS Profile‐29 in adults with hemophilia in the Netherlands
por: van Balen, Erna C., et al.
Publicado: (2021)

Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972–2019
por: Hassan, Shermarke, et al.
Publicado: (2021)

Genetic analysis of carrier status in female members of Japanese hemophilia families
por: Shinozawa, Keiko, et al.
Publicado: (2021)

The experiences and attitudes of hemophilia carriers around pregnancy: A qualitative systematic review
por: Punt, Marieke C., et al.
Publicado: (2020)

Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001–2018
por: Hassan, Shermarke, et al.
Publicado: (2020)

The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli
por: Chernysh, Irina N., et al.
Publicado: (2020)

Validity and reliability of the Colorado Adult Joint Assessment Scale in adults with moderate‐severe hemophilia A
por: Funk, Sharon M., et al.
Publicado: (2019)

Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non‐severe haemophilia A
por: Rejtő, Judit, et al.
Publicado: (2020)

Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach
por: Winterling, Karina, et al.
Publicado: (2021)

Characterization of interaction between blood coagulation factor VIII and LRP1 suggests dynamic binding by alternating complex contacts
por: Chun, Haarin, et al.
Publicado: (2022)

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort
por: Pasi, K. John, et al.
Publicado: (2021)

Detailed analysis of anti‐emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A
por: Kaneda, Makoto, et al.
Publicado: (2021)

Management of von Willebrand disease with a factor VIII‐poor von Willebrand factor concentrate: Results from a prospective observational post‐marketing study
por: Goudemand, Jenny, et al.
Publicado: (2020)

Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)
por: Klamroth, Robert, et al.
Publicado: (2019)

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study
por: Abdi, Amal, et al.
Publicado: (2021)

Identification of deep intronic individual variants in patients with hemophilia A by next‐generation sequencing of the whole factor VIII gene
por: Inaba, Hiroshi, et al.
Publicado: (2017)

Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
por: Coyle, T E, et al.
Publicado: (2014)

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2019)

Efficacy of fibrinogen concentrate in major abdominal surgery – A prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei
por: Roy, Ashok, et al.
Publicado: (2019)

Blockade of the costimulatory CD28‐B7 family signal axis enables repeated application of AAV8 gene vectors
por: Frentsch, Marco, et al.
Publicado: (2020)

Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
por: Nederpelt, Charlie J., et al.
Publicado: (2020)

A novel assay for studying the involvement of blood cells in whole blood thrombin generation
por: Wan, Jun, et al.
Publicado: (2020)

Coagulopathy signature precedes and predicts severity of end‐organ heat stroke pathology in a mouse model
por: Proctor, Elizabeth A., et al.
Publicado: (2020)

Performance of factor IX extended half‐life product measurements in external quality control assessment programs
por: Nederlof, Angelique, et al.
Publicado: (2020)

Efficacy of pro‐ and anticoagulant strategies in plasma of patients undergoing hepatobiliary surgery
por: Bos, Sarah, et al.
Publicado: (2020)

The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice
por: Buijs, Jeroen T., et al.
Publicado: (2019)

Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII‐equivalence
por: Leksa, Nina C., et al.
Publicado: (2019)

Thromboelastography‐guided therapy improves patient blood management and certain clinical outcomes in elective cardiac and liver surgery and emergency resuscitation: A systematic review and analysis
por: Dias, João D., et al.
Publicado: (2019)

Temperature‐dependent irreversible conformational change of recombinant ADAMTS13 upon metal ion chelation
por: Rottensteiner, Hanspeter, et al.
Publicado: (2019)

Effect of multidose drug dispensing on the time in therapeutic range in patients using vitamin‐K antagonists: A randomized controlled trial
por: Mertens, Bram J., et al.
Publicado: (2019)

One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P(®)/Humate P(®) treatment in von Willebrand disease patients
por: de Jager, Nico C. B., et al.
Publicado: (2019)

Hydrogen‐deuterium exchange mass spectrometry highlights conformational changes induced by factor XI activation and binding of factor IX to factor XIa
por: Bar Barroeta, Awital, et al.
Publicado: (2019)

Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants
por: Testa, Sophie, et al.
Publicado: (2019)

Fibrinogen αC‐regions are not directly involved in fibrin polymerization as evidenced by a “Double‐Detroit” recombinant fibrinogen mutant and knobs‐mimic peptides
por: Duval, Cédric, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_70nt418mov1e50t1idlh3tsioc